Characterization of the novel HLA-A*03:01:102 allele by next-generation sequencing.

Alleles Exons / genetics HLA-A Antigens / genetics High-Throughput Nucleotide Sequencing Humans Nucleotides
HLA polymorphism NGS new allele

Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
10 2021
Historique:
received: 01 07 2021
accepted: 04 07 2021
pubmed: 8 7 2021
medline: 3 11 2021
entrez: 7 7 2021
Statut: ppublish

Résumé

HLA-A*03:01:102 differs from HLA-A*03:01:01:01 by one nucleotide substitution at position 72 in exon 1.

Identifiants

DOI: 10.1111/tan.14358 PMID: 34231335
pubmed: 34231335
doi: 10.1111/tan.14358
doi:

Substances chimiques

HLA-A Antigens 0
Nucleotides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

382-383

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA Database. Nucleic Acids Res. 2020;48:D948-D955.
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75:291-455.

Auteurs

Maria Loginova (M)

Federal State Budget Research Institution: Kirov Hematology and Blood Transfusion Research Institute under the Federal Medicine and Biology Agency, Kirov, Russia.
ORCID: 0000-0001-7088-3986

Daria Smirnova (D)

Federal State Budget Research Institution: Kirov Hematology and Blood Transfusion Research Institute under the Federal Medicine and Biology Agency, Kirov, Russia.

Svetlana Kutyavina (S)

Federal State Budget Research Institution: Kirov Hematology and Blood Transfusion Research Institute under the Federal Medicine and Biology Agency, Kirov, Russia.

Igor Paramonov (I)

Federal State Budget Research Institution: Kirov Hematology and Blood Transfusion Research Institute under the Federal Medicine and Biology Agency, Kirov, Russia.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Allèles › Characterization of the novel HLA-A*03:01:102...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Composants de gène › Exons › Characterization of the novel HLA-A*03:01:102...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › Antigènes HLA-A › Characterization of the novel HLA-A*03:01:102...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Characterization of the novel HLA-A*03:01:102...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Characterization of the novel HLA-A*03:01:102...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Characterization of the novel HLA-A*03:01:102...